UY23697A1 - Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo - Google Patents
Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarboniloInfo
- Publication number
- UY23697A1 UY23697A1 UY23697A UY23697A UY23697A1 UY 23697 A1 UY23697 A1 UY 23697A1 UY 23697 A UY23697 A UY 23697A UY 23697 A UY23697 A UY 23697A UY 23697 A1 UY23697 A1 UY 23697A1
- Authority
- UY
- Uruguay
- Prior art keywords
- radical
- formula
- deoxy
- integer
- protecting groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere al procedimiento para preparar un compuesto de fórmula general (I) (ver figura 1) derivados de N4-(oxicarbonil sustituidos)-5'-desoxi-5-fuorocitidina, así como también hidratos o solvatos de dichos compuestos, donde: R1 es un radical hidrocarburo saturado o insaturado; R2 es un átomo de hidrógeno o un radical fácilmente hidrolizable en condiciones fisiológicas. El procedimiento comprende la reacción de un compuesto de fórmula general (II) (figura 2), donde R4 es un radical de protección de los hidroxilos con un compuesto: R1OCOC1, y si es necesario se eliminan los radicales de protección. Ejemplo no limitante: 5'-desoxi-5-fluoro-N4-[(1,1,2-trimetilpropoxi)carbonil]citidina. Los productos según la invención son de utilidad para el tratamiento de tumores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92121538 | 1992-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY23697A1 true UY23697A1 (es) | 1994-06-08 |
Family
ID=8210304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY23697A UY23697A1 (es) | 1992-12-18 | 1993-12-17 | Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo |
Country Status (41)
Country | Link |
---|---|
US (1) | US5472949A (es) |
EP (1) | EP0602454B1 (es) |
JP (1) | JP2501297B2 (es) |
KR (1) | KR100347218B1 (es) |
CN (1) | CN1035617C (es) |
AT (1) | ATE137244T1 (es) |
AU (1) | AU671491B2 (es) |
BG (1) | BG61485B1 (es) |
BR (1) | BR9305089A (es) |
CA (1) | CA2103324C (es) |
CZ (1) | CZ284788B6 (es) |
DE (1) | DE69302360T2 (es) |
DK (1) | DK0602454T3 (es) |
EE (1) | EE03086B1 (es) |
ES (1) | ES2086856T3 (es) |
FI (1) | FI112365B (es) |
GE (1) | GEP20074251B (es) |
GR (1) | GR3020286T3 (es) |
HK (1) | HK1005875A1 (es) |
HR (1) | HRP931430B1 (es) |
HU (2) | HU218291B (es) |
IL (1) | IL108000A0 (es) |
IS (1) | IS4108A (es) |
LT (1) | LT3115B (es) |
LV (1) | LV10625B (es) |
MY (1) | MY109282A (es) |
NO (1) | NO300066B1 (es) |
NZ (1) | NZ250414A (es) |
PH (1) | PH30168A (es) |
PL (1) | PL174100B1 (es) |
RO (1) | RO112619B1 (es) |
RU (2) | RU2493162C1 (es) |
SA (1) | SA93140409B1 (es) |
SI (1) | SI9300648B (es) |
SK (1) | SK281403B6 (es) |
SV (1) | SV1993000080A (es) |
TW (1) | TW372239B (es) |
UA (1) | UA39158C2 (es) |
UY (1) | UY23697A1 (es) |
YU (1) | YU49411B (es) |
ZA (1) | ZA939293B (es) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476932A (en) * | 1994-08-26 | 1995-12-19 | Hoffmann-La Roche Inc. | Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives |
EP0882734B1 (en) * | 1997-06-02 | 2009-08-26 | F. Hoffmann-La Roche Ag | 5'-Deoxy-cytidine derivatives |
NZ330360A (en) * | 1997-06-02 | 1999-03-29 | Hoffmann La Roche | 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents |
US6005098A (en) * | 1998-02-06 | 1999-12-21 | Hoffmann-La Roche Inc. | 5'deoxycytidine derivatives |
ES2185378T3 (es) * | 1998-09-25 | 2003-04-16 | Warner Lambert Co | Quimioterapia de cancer con acetildinalina en combinacion con gemcitabina, capecitabina o cisplatina. |
US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
US20070122481A1 (en) * | 1998-11-02 | 2007-05-31 | Elan Corporation Plc | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer |
ES2273841T3 (es) | 2000-02-28 | 2007-05-16 | Pfizer Enterprises Sarl | Combinacion sinergica para el tratamiento de cancer colorrectal. |
AU2001246863A1 (en) * | 2000-04-11 | 2001-10-23 | Sayuri Yamada | Curcumin compositions |
KR100730768B1 (ko) * | 2000-08-09 | 2007-06-21 | 코오롱생명과학 주식회사 | 5'-데옥시-n-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법 |
KR100631754B1 (ko) * | 2000-08-09 | 2006-10-09 | 주식회사 코오롱 | N-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법 |
WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
GB0113374D0 (en) * | 2001-06-04 | 2001-07-25 | Jerram Clare | Washing line umbrella |
AU2003235761A1 (en) * | 2002-01-14 | 2003-07-24 | Novartis Ag | Combinations comprising epothilones and anti-metabolites |
BR0316238A (pt) * | 2002-11-15 | 2005-10-11 | Warner Lambert Co | Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer |
AU2003233586A1 (en) * | 2003-05-20 | 2005-01-21 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising capecitabine and a liposomal platinum complex |
EP1689404B9 (en) * | 2003-11-13 | 2009-04-22 | Pharma Mar, S.A.U. | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer |
CA2550299C (en) * | 2003-12-22 | 2010-03-30 | Christopher R. Roberts | Process for fluorocytidine derivatives |
WO2006084058A2 (en) | 2005-02-03 | 2006-08-10 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
WO2006103187A2 (en) * | 2005-04-01 | 2006-10-05 | F. Hoffmann-La Roche Ag | Method for administration of capecitabine |
ZA200800907B (en) | 2005-07-18 | 2010-04-28 | Bipar Sciences Inc | Treatment of cancer |
ES2384267T3 (es) | 2005-07-21 | 2012-07-03 | Nuvo Research Ag | Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer |
WO2007056118A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
HUE030235T2 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
US20080085310A1 (en) * | 2006-10-06 | 2008-04-10 | Maria Oksana Bachynsky | Capecitabine rapidly disintegrating tablets |
CN100425617C (zh) * | 2006-10-31 | 2008-10-15 | 浙江海正药业股份有限公司 | 一种含氟嘧啶类化合物烷氧羰酰化的方法 |
ITMI20070435A1 (it) | 2007-03-05 | 2008-09-06 | Innovate Biotechnology Srl | 2',3'-di-o-acil-5-fluoronucleosidi |
EP2137201A2 (en) * | 2007-04-20 | 2009-12-30 | Dr. Reddy's Laboratories Ltd. | Process for preparing capecitabine |
EP2164856A1 (en) * | 2007-06-01 | 2010-03-24 | Synthon B.V. | Processes related to making capecitabine |
EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
US7842675B2 (en) * | 2007-09-15 | 2010-11-30 | Protia, Llc | Deuterium-enriched capecitabine |
WO2009042064A2 (en) | 2007-09-21 | 2009-04-02 | Nektar Therapeutics Al, Corporation | Oligomer-nucleoside phosphate conjugates |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
KR101013312B1 (ko) * | 2007-11-19 | 2011-02-09 | 한미홀딩스 주식회사 | 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법 |
AR064165A1 (es) | 2007-12-06 | 2009-03-18 | Richmond Sa Com Ind Y Financie | Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento |
US20090209754A1 (en) * | 2008-01-03 | 2009-08-20 | Macdonald Peter Lindsay | Process for the preparation of capecitabine |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
ES2614912T3 (es) | 2008-08-04 | 2017-06-02 | Wyeth Llc | Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina |
WO2010065586A2 (en) * | 2008-12-02 | 2010-06-10 | Dr. Reddy's Laboratories Ltd. | Preparation of capecitabine |
US8603999B2 (en) | 2008-12-05 | 2013-12-10 | Commonwealth Scientific And Industrial Research Organisation | Amphiphile prodrugs |
EP3000467B1 (en) | 2009-04-06 | 2023-03-01 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
FR2945211A1 (fr) | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
EA020494B1 (ru) | 2009-05-22 | 2014-11-28 | Инсайт Корпорейшн | 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ |
WO2011010967A1 (en) * | 2009-07-23 | 2011-01-27 | Scinopharm Taiwan Ltd. | Process for producing flurocytidine derivatives |
WO2011067588A1 (en) | 2009-12-04 | 2011-06-09 | Generics [Uk] Limited | Cyclic sulphinyl esters of cytidine |
WO2011104540A1 (en) * | 2010-02-24 | 2011-09-01 | Generics [Uk] Limited | One step process for the preparation of capecitabine |
MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
HUE040107T2 (hu) | 2010-03-12 | 2019-02-28 | Genzyme Corp | Kombinációs terápia mellrák kezelésére |
EP3087972A1 (en) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
CN102260309B (zh) * | 2010-05-24 | 2014-10-22 | 重庆福安药业(集团)股份有限公司 | 一种高纯度卡培他滨的制备方法 |
SG190839A1 (en) | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
CN102558262A (zh) * | 2010-12-23 | 2012-07-11 | 天津泰普药品科技发展有限公司 | 一种高纯度卡培他滨的制备方法 |
AR086983A1 (es) | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
CN102266303A (zh) * | 2011-07-07 | 2011-12-07 | 程雪翔 | 一种卡培他滨药用组合物及其制备方法 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CN102516338B (zh) * | 2011-12-09 | 2014-04-02 | 海南锦瑞制药股份有限公司 | 一种卡培他滨化合物、其药物组合物及其制备方法 |
TWI560195B (en) * | 2012-01-13 | 2016-12-01 | Pharmaessentia Corp | Novel synthesis of 5-deoxy-5'-fluorocytidine compounds |
KR20220162825A (ko) | 2012-11-15 | 2022-12-08 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
AU2014225938B2 (en) | 2013-03-06 | 2018-07-19 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
KR20160045081A (ko) | 2013-08-07 | 2016-04-26 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
SG11201601119XA (en) * | 2013-08-20 | 2016-03-30 | Incyte Corp | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
EP2883959A1 (en) | 2013-12-13 | 2015-06-17 | Plasmia Biotech, S.L. | Enzymatic production of cytosinic nucleoside analogues |
CN103897006A (zh) * | 2013-12-18 | 2014-07-02 | 吉林修正药业新药开发有限公司 | 一种卡培他滨异构体的制备方法 |
US10080807B2 (en) | 2014-06-09 | 2018-09-25 | Lipomedix Pharmaceuticals Ltd. | Combination chemotherapy comprising a liposomal prodrug of mitomycin C |
CN104530164A (zh) * | 2014-12-31 | 2015-04-22 | 辰欣药业股份有限公司 | 一种卡培他滨的合成工艺 |
KR20160117060A (ko) | 2015-03-31 | 2016-10-10 | 이승주 | 유아용 탁자 |
CN105646625B (zh) * | 2015-12-29 | 2019-06-11 | 江苏吴中医药集团有限公司 | 一种卡培他滨的制备方法 |
WO2018129533A1 (en) | 2017-01-09 | 2018-07-12 | Shuttle Pharmaceuticals, Llc | Selective histone deacetylase inhibitors for the treatment of human disease |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
TR201702500A2 (tr) * | 2017-02-20 | 2017-07-21 | Anadolu Ueniversitesi | Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi |
US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
EP3737376B1 (en) | 2018-01-09 | 2024-04-17 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human diseases |
CN111801339A (zh) * | 2018-01-19 | 2020-10-20 | 纽科利制药公司 | 5-氟尿嘧啶化合物 |
US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
TWI797242B (zh) | 2018-01-30 | 2023-04-01 | 美商英塞特公司 | 製備jak抑制劑之方法及中間物 |
MX2022012285A (es) | 2018-03-30 | 2023-08-15 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
JP2022517352A (ja) | 2019-01-11 | 2022-03-08 | リポメディックス・ファーマシューティカルズ・リミテッド | マイトマイシンcのリポソーム化プロドラッグを含むリポソーム組成物および製造法 |
JP2023523415A (ja) | 2020-04-21 | 2023-06-05 | リガンド・ファーマシューティカルズ・インコーポレイテッド | ヌクレオチドプロドラッグ化合物 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2023177894A1 (en) | 2022-03-18 | 2023-09-21 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and an antimetabolite agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1135258A (en) * | 1979-06-15 | 1982-11-09 | Richard D'souza | Process for the preparation of 5'deoxy-5-fluorouridine |
IL77133A (en) * | 1984-12-04 | 1991-01-31 | Lilly Co Eli | Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation |
CA1327358C (en) * | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
-
1993
- 1993-11-12 AU AU50690/93A patent/AU671491B2/en not_active Expired
- 1993-11-15 TW TW082109533A patent/TW372239B/zh not_active IP Right Cessation
- 1993-11-17 CA CA002103324A patent/CA2103324C/en not_active Expired - Lifetime
- 1993-11-23 HR HR92121538.0A patent/HRP931430B1/xx not_active IP Right Cessation
- 1993-12-01 DK DK93119349.4T patent/DK0602454T3/da active
- 1993-12-01 ES ES93119349T patent/ES2086856T3/es not_active Expired - Lifetime
- 1993-12-01 EP EP93119349A patent/EP0602454B1/en not_active Expired - Lifetime
- 1993-12-01 DE DE69302360T patent/DE69302360T2/de not_active Expired - Lifetime
- 1993-12-01 AT AT93119349T patent/ATE137244T1/de active
- 1993-12-07 SA SA93140409A patent/SA93140409B1/ar unknown
- 1993-12-10 SI SI9300648A patent/SI9300648B/sl unknown
- 1993-12-10 HU HU9303525A patent/HU218291B/hu active Protection Beyond IP Right Term
- 1993-12-10 NZ NZ250414A patent/NZ250414A/en not_active IP Right Cessation
- 1993-12-10 ZA ZA939293A patent/ZA939293B/xx unknown
- 1993-12-13 IL IL10800093A patent/IL108000A0/xx not_active IP Right Cessation
- 1993-12-13 CZ CZ932731A patent/CZ284788B6/cs not_active IP Right Cessation
- 1993-12-14 US US08/167,392 patent/US5472949A/en not_active Expired - Lifetime
- 1993-12-14 FI FI935616A patent/FI112365B/fi not_active IP Right Cessation
- 1993-12-15 YU YU77993A patent/YU49411B/sh unknown
- 1993-12-15 RO RO93-01706A patent/RO112619B1/ro unknown
- 1993-12-15 PH PH47455A patent/PH30168A/en unknown
- 1993-12-16 BG BG98304A patent/BG61485B1/bg unknown
- 1993-12-16 RU RU2012134029/04A patent/RU2493162C1/ru not_active IP Right Cessation
- 1993-12-16 BR BR9305089A patent/BR9305089A/pt not_active Application Discontinuation
- 1993-12-16 JP JP5342812A patent/JP2501297B2/ja not_active Expired - Fee Related
- 1993-12-16 RU RU93056196/04A patent/RU2458932C2/ru active Protection Beyond IP Right Term
- 1993-12-16 MY MYPI93002726A patent/MY109282A/en unknown
- 1993-12-16 KR KR1019930027962A patent/KR100347218B1/ko not_active IP Right Cessation
- 1993-12-17 NO NO934671A patent/NO300066B1/no not_active IP Right Cessation
- 1993-12-17 CN CN93112838A patent/CN1035617C/zh not_active Expired - Lifetime
- 1993-12-17 LT LTIP1627A patent/LT3115B/lt not_active IP Right Cessation
- 1993-12-17 UY UY23697A patent/UY23697A1/es not_active IP Right Cessation
- 1993-12-17 IS IS4108A patent/IS4108A/is unknown
- 1993-12-17 PL PL93301541A patent/PL174100B1/pl unknown
- 1993-12-17 UA UA93004687A patent/UA39158C2/uk unknown
- 1993-12-17 SV SV1993000080A patent/SV1993000080A/es not_active Application Discontinuation
- 1993-12-17 SK SK1444-93A patent/SK281403B6/sk not_active IP Right Cessation
- 1993-12-17 LV LVP-93-1347A patent/LV10625B/en unknown
-
1994
- 1994-11-18 EE EE9400154A patent/EE03086B1/xx not_active IP Right Cessation
-
1995
- 1995-06-19 HU HU95P/P00255P patent/HU211965A9/hu unknown
-
1996
- 1996-06-19 GR GR960401668T patent/GR3020286T3/el unknown
-
1998
- 1998-06-05 HK HK98105008A patent/HK1005875A1/xx not_active IP Right Cessation
-
2006
- 2006-07-17 GE GEAP20069525A patent/GEP20074251B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY23697A1 (es) | Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo | |
RU93056196A (ru) | N-карбонилзамещенные 5'-дезокси-5-фторцитидина | |
EG18944A (en) | (Benzylidene) - Azolylmethylcycloalkane and use as fungicide | |
DE68905627T2 (de) | Hydrophile sauerstoffdurchlaessige polymere. | |
CA2065978A1 (en) | Organosilicon compounds containing (meth)acryloxy groups, their preparation and use | |
FR2702480B1 (fr) | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. | |
HU9202367D0 (en) | Preparative for reducing blood pressure | |
EP0401715A3 (en) | Aminoketone compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
VENC | Patent expired |
Effective date: 20131116 |